AFos dissociates cardiac myocyte hypertrophy and expression of the pathological gene program

Keyphrases

• Cardiac Hypertrophy 100%
• Activator protein-1 (AP-1) 100%
• Gene Programs 100%
• C-Fos 50%
• Myosin Heavy Chain (MyHC) 50%
• SERCA 50%
• Gene Profile 50%
• Overexpression 25%
• Gene Expression 25%
• Hypertrophy 25%
• Myocytes 25%
• Growth Response 25%
• Oncogene 25%
• Actin 25%
• Treatment Group 25%
• MAP3K 25%
• Phenylephrine 25%
• Adenoviral 25%
• Dominant-negative mutant 25%
• Myocardial Development 25%
• Constitutively Active 25%
• Brain Natriuretic Peptide 25%
• Fetal Gene Program 25%
• Neonatal Rat Cardiomyocytes 25%
• Transcription Factor Activity 25%
• MKK6 25%
• Sarcoplasmic Reticulum Ca2+-ATPase 25%

Medicine and Dentistry

• Transcription Factor AP 1 100%
• Cardiac Muscle Cell 100%
• Oncogene C Fos 66%
• Brain Natriuretic Peptide 66%
• Heavy Meromyosin 66%
• Gene Expression 33%
• Adenosine Triphosphatase 33%
• Actin 33%
• Calcium Ion 33%
• Upregulation 33%
• Phenylephrine 33%
• Ventricular Hypertrophy 33%
• Proto Oncogene 33%
• Sarcoplasmic reticulum 33%
• Activator Protein 1 33%
• Muscle Cell 33%

Biochemistry, Genetics and Molecular Biology

• Cardiac Muscle Cell 100%
• AP-1 Transcription Factor 100%
• C-Fos 66%
• Heavy Meromyosin 66%
• SERCA 66%
• Brain Natriuretic Peptide 66%
• Upregulation 33%
• Agonist 33%
• ATPase 33%
• Gene Expression 33%
• Actin 33%
• Proto Oncogene 33%
• Activator Protein 1 33%
• Phenylephrine 33%